Metabolic dysfunction: The silenced connection with fatty liver disease

Area of Science:

• Hepatology
• Metabolic Diseases
• Public Health

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a growing global health concern, often overshadowed by related conditions like diabetes and obesity.
• Despite its prevalence, NAFLD has historically lacked sufficient research focus and clear diagnostic criteria.
• The metabolic underpinnings of fatty liver disease are increasingly recognized as central to its pathophysiology.

Purpose of the Study:

• To review the historical context and scientific rationale for renaming NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD).
• To examine the pathophysiological mechanisms linking metabolic dysfunction to fatty liver disease.
• To discuss the clinical implications and benefits of adopting the MAFLD classification and diagnostic criteria.

Main Methods:

• Literature review of historical, pathophysiological, and clinical studies related to fatty liver disease.
• Analysis of proposed diagnostic criteria for MAFLD.
• Comparative assessment of NAFLD versus MAFLD nomenclature and clinical scope.

Main Results:

• The proposed MAFLD criteria aim to encompass the full spectrum of fatty liver disease driven by metabolic dysfunction.
• Renaming acknowledges the primary role of metabolic factors, irrespective of BMI or co-existing liver conditions.
• The MAFLD approach facilitates a more accurate diagnosis and targeted management strategies.

Conclusions:

• The transition from NAFLD to MAFLD represents a crucial paradigm shift in understanding and managing fatty liver disease.
• MAFLD provides a more precise and inclusive framework, emphasizing metabolic health in liver disease.
• Adopting MAFLD is essential for advancing research, diagnosis, and treatment of metabolic-associated fatty liver disease.